Technical Articles

CXCL9 (MIG) is an IFN-γ-inducible CXC chemokine signaling through CXCR3. This article explains its induction logic, T-cell recruitment role and how recombinant human CXCL9 supports chemotaxis and receptor-binding experiments.

At the forefront of cancer treatment, CAR-T cell therapy is gradually becoming a powerful weapon to conquer tumors. However, when facing solid tumors, the effect of CAR-T cell therapy is not ideal. This is because the tumor microenvironment of solid tumors is like a solid line of defense, hindering the infiltration of immune cells.